Keytruda also requires an IV infusion every month in a clinic or hospital while leronlimab can be self administered at home. It would be tough to justify the added time, cost, and possible side effects if it truly were redundant to leronlimab. The question will be how to finance and do that ethically with IRB approval in cancers where Keytruda is currently beneficial.